VTVT Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
vTv Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.59 |
| 52 Week High | US$30.99 |
| 52 Week Low | US$7.38 |
| Beta | 0.63 |
| 11 Month Change | -2.41% |
| 3 Month Change | -17.01% |
| 1 Year Change | -22.51% |
| 33 Year Change | -77.34% |
| 5 Year Change | -75.52% |
| Change since IPO | -96.65% |
Recent News & Updates
Recent updates
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Aug 24
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
May 11vTv Therapeutics GAAP EPS of -$0.04
Aug 16vTv stock soars 18% on $10M equity investment by CinRx Pharma
Jul 25We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Aug 17The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares
Mar 03vTv Therapeutics inks licensing deal for HPP971, shares up 11%
Dec 15MacAndrews & Forbes buys 625K shares of vTv Therapeutics
Dec 11Shareholder Returns
| VTVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.1% | -0.5% | 0.3% |
| 1Y | -22.5% | 18.0% | 32.4% |
Return vs Industry: VTVT underperformed the US Biotechs industry which returned 17.6% over the past year.
Return vs Market: VTVT underperformed the US Market which returned 32.5% over the past year.
Price Volatility
| VTVT volatility | |
|---|---|
| VTVT Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VTVT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VTVT's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 16 | Paul Sekhri | vtvtherapeutics.com |
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.
vTv Therapeutics Inc. Fundamentals Summary
| VTVT fundamental statistics | |
|---|---|
| Market cap | US$42.74m |
| Earnings (TTM) | -US$20.18m |
| Revenue (TTM) | US$1.00m |
35.5x
P/S Ratio-1.8x
P/E RatioIs VTVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTVT income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$13.68m |
| Gross Profit | -US$12.67m |
| Other Expenses | US$7.50m |
| Earnings | -US$20.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.29 |
| Gross Margin | -1,267.50% |
| Net Profit Margin | -2,017.70% |
| Debt/Equity Ratio | 0% |
How did VTVT perform over the long term?
See historical performance and comparison